Shanghai Sigma-Audley New Material Technology: difference between revisions

Diff·revision 20 → 21·17:39, 30 Jan 2025

Difference between revision 20 and revision 21 of Shanghai Sigma-Audley New Material Technology. 8 lines changed; the page grew by 404 bytes.

Revision 20 — 21:53, 21 Jan 2025 PlainNumbersPip (talk) fix unit 5,695 bytes +526	Revision 21 — 17:39, 30 Jan 2025 SafetySignalSid (talk) cite the trial publication rather than the press release 6,099 bytes +404
32	The organisation's own material describes a product range and documentation practice; it makes no certification claim that this wiki has been able to corroborate, and any such claim would in any case require assessment against the applicable framework rather than acceptance at face value.{{r\|gmp,selfpub}}	32	The organisation's own material describes a product range and documentation practice; it makes no certification claim that this wiki has been able to corroborate, and any such claim would in any case require assessment against the applicable framework rather than acceptance at face value.{{r\|gmp,selfpub}}
33		33
+		34	== Product range ==
+		35	\| Class \| Representative listings \| Documentation reported \|
+		36	\|---\|---\|---\|
+		37	\| Incretin analogues \| Semaglutide, tirzepatide, retatrutide \| Batch certificate, HPLC trace \|
+		38	\| Research peptides \| Repair and secretagogue peptides \| Batch certificate \|
+		39	\| SARMs \| Bulk and capsuled \| Certificate, variable detail \|
+		40	\| Injectable oils and raw materials \| Bulk \| Certificate, limited detail \|
+		41
34	== References ==	42	== References ==
35	{{reflist}}	43	{{reflist}}